In this episode of The Dales Report Psychedelic Exclusive, we sit down again with our good friend Doug Drysdale, the CEO of Cybin (NYSEAMERICAN: CYBN). He’s been on the podcast recently to discuss Cybin’s patent approvals and summaries on the company’s new investments for investors, so be sure to check out these previous episodes. Today, he’s going over the company’s latest research developments with host Shadd Dales and lead financial writer Benjamin A. Smith.
In case you missed it, the much-anticipated Phase 2 findings on CYB003 were revealed this week. CYB003 is a psilocybin analog, and the study was focused on whether the compound could reduce depression symptoms. So far, CYB003 is yielding some impressive results.
Doug explains how these findings show the potential for psychedelics in the field of psychiatric pharmacology. Could this be the future of mental health, and will this bring a new era of research and development in mental health treatments? The optimized molecule’s potency and effects have gained excitement in the industry, with experts considering these findings a huge leap forward.
We talk with Doug in depth about the results of the Cybin study, and whether a brighter future lies ahead. While of course this is great news for people looking for treatment, we also explore hints at the substantial impact these developments could have on the psychedelics market itself.
Where does Cybin go from here? We talk about strategic partnerships, the market reactions to the groundbreaking data, and potential alternatives to current treatments for mental health disorders. There’s room for future breakthroughs with CYB003 and other compounds that the company is working on, and we aim to give viewers a sneak peek into the potential of Cybin’s work.
Don’t miss out on tuning in to this interview to hear about the trial’s exciting results and impact you might see if investing.
* In accordance with an executed agreement between The Dales Report and Cybin, The Dales Report is engaged with the aforementioned on a 6-month contract for $7,500 per month, with the purpose of publicly disseminating information pertaining to Cybin via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer.